Figure 2.

Odds ratios for developing colorectal cancer in different MPRs for selective COX-2 inhibitors. (Note: Significant odds ratios are at 10% and 20% of 5-year cumulative usage, at 10% to 40% of 3-year usage, at 10% to 80% of 1-year usage, and at 30% to 60% and 80% of 6-month usage).

Yang et al. BMC Cancer 2012 12:582   doi:10.1186/1471-2407-12-582
Download authors' original image